{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:09:50Z","timestamp":1783350590223,"version":"3.54.6"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blinatumomab has transformed the treatment of pediatric B\u2010acute lymphoblastic leukemia (B\u2010ALL). However, it presents distinct operational challenges for administration given it is delivered as a continuous infusion and has unique toxicities. The objective of this project was to develop, implement, and evaluate a standardized institutional protocol for blinatumomab administration to optimize safety, efficiency, and patient experience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Procedure<\/jats:title>\n                    <jats:p>This quality improvement (QI) initiative was conducted at The Hospital for Sick Children, Toronto, Canada. A multidisciplinary Blinatumomab Working Group developed harmonized standards across five domains: (1) caregiver education, (2) fever management, (3) nursing\u2010led assessments, (4) infusion interruption management, and (5) use of 7\u2010day infusion bags. Patients receiving blinatumomab for upfront therapy or for relapsed disease between July 2024 and August 2025 were included. Demographic and clinical data were extracted from the institutional data warehouse. Outcomes included rates of caregiver education completion, antibiotic use during blinatumomab initiation, and completion of nursing\u2010led assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty\u2010three patients received standard of care blinatumomab. All eligible caregivers (100%) completed standardized education. The rate of empiric antibiotic use during blinatumomab initiation decreased from 68% to 22% following adoption of selective antibiotic initiation without increased readmission, or prolonged stay. Nursing assessment completion was 95% for inpatients and 81% for outpatients. Infusion interruptions were managed using a standardized, risk\u2010based algorithm without observed safety events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Implementation of multidisciplinary, standardized blinatumomab administration protocols was feasible and safe. These processes improved antibiotic stewardship, empowered nursing\u2010led care, and reduced practice variability. This framework may inform best practices for the safe and efficient delivery of blinatumomab in other pediatric oncology centers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/1545-5017.70137","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:55:27Z","timestamp":1769090127000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Creation of Blinatumomab Administration Standards: A Single Institution's Experience"],"prefix":"10.1002","volume":"73","author":[{"given":"Sue","family":"Zupanec","sequence":"first","affiliation":[{"name":"Division of Haematology\/Oncology The Hospital for Sick Children  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Honeyford","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology The Hospital for Sick Children  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Starr","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology The Hospital for Sick Children  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Petropolous","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology The Hospital for Sick Children  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Stitovic","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology The Hospital for Sick Children  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Culko","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology The Hospital for Sick Children  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Feng","sequence":"additional","affiliation":[{"name":"Program in Child Health Evaluative Sciences Peter Gilgan Centre For Research and Learning The Hospital for Sick Children  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia Maria Carlotta","family":"Arnaboldi","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology The Hospital for Sick Children  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-3670","authenticated-orcid":false,"given":"Sumit","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology The Hospital for Sick Children  Toronto Canada"},{"name":"Program in Child Health Evaluative Sciences Peter Gilgan Centre For Research and Learning The Hospital for Sick Children  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8300-3095","authenticated-orcid":false,"given":"Adam P.","family":"Yan","sequence":"additional","affiliation":[{"name":"Division of Haematology\/Oncology The Hospital for Sick Children  Toronto Canada"},{"name":"Program in Child Health Evaluative Sciences Peter Gilgan Centre For Research and Learning The Hospital for Sick Children  Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad115"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010023\u201001870\u20108"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01086"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00494"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.10509"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3301"},{"key":"e_1_2_7_8_1","article-title":"Blinatumomab in Pediatric Patients With Relapsed\/Refractory (R\/R) B\u2010Cell Precursor Acute Lymphoblastic Leukaemia (BCP\u2010ALL): A Phase I\/II Study","volume":"37","author":"Locatelli F.","year":"2014","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201099\u2010117051"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0669"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411680"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1188\/25.CJON.303\u2010312"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31913"},{"key":"e_1_2_7_15_1","unstructured":"Amgen Inc \u201cBLINCYTO\u00ae (Blinatumomab) \u201dAmgen Inc accessed November 4 2025 https:\/\/www.blincytohcp.com\/dosing."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(25)00128\u20107"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31223"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/CCI\u201024\u201000306"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31824"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21586"},{"key":"e_1_2_7_21_1","unstructured":"\u201cMeasure the Readability of Text \u201dReadable accessed August 22 2025 https:\/\/app.readable.com\/text\/?demo."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1090198105277329"},{"key":"e_1_2_7_23_1","unstructured":"\u201cThe Patient Education Materials Assessment Tool (PEMAT) and User's Guide \u201dAgency for Healthcare Research and Quality accessed August 22 2025 https:\/\/www.ahrq.gov\/es\/health\u2010literacy\/patient\u2010education\/pemat1.html."},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2005.25.9.1277"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-25804-7_6"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13187\u2010025\u201002584\u20104"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010025\u201009693\u20102"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1545-5017.70137","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/1545-5017.70137","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/1545-5017.70137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T12:24:38Z","timestamp":1779539078000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/1545-5017.70137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/1545-5017.70137"],"URL":"https:\/\/doi.org\/10.1002\/1545-5017.70137","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"2025-11-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70137"}}